Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients

Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients

Potent antiviral agents effectively reduce liver-related events in patients with chronic hepatitis B. This study aimed to determine whether alanine aminotransferase normalization using potent antiviral agents was related to hepatocellular carcinoma development. From 2007 to 2017, we included 610 pat...

Full description

Bibliographic Details
Main Authors: Sehwa Kim, Yoonseok Lee, Soo Min Bang, Haein Bak, Sun Young Yim, Young Sun Lee, Yang Jae Yoo, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Kwan Soo Byun, Jong Eun Yeon
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
alt normalization
hcc
entecavir
tenofovir
Online Access:https://www.mdpi.com/2077-0383/10/9/1840
id doaj-166a52d7837c4d7ab812e76ca076d823
record_format Article
spelling doaj-166a52d7837c4d7ab812e76ca076d8232021-04-23T23:05:04ZengMDPI AGJournal of Clinical Medicine2077-03832021-04-01101840184010.3390/jcm10091840Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV PatientsSehwa Kim0Yoonseok Lee1Soo Min Bang2Haein Bak3Sun Young Yim4Young Sun Lee5Yang Jae Yoo6Young Kul Jung7Ji Hoon Kim8Yeon Seok Seo9Hyung Joon Yim10Soon Ho Um11Kwan Soo Byun12Jong Eun Yeon13Department of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam-si 13590, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaDepartment of Internal Medicine, Korea University College of Medicine, Seoul 08308, KoreaPotent antiviral agents effectively reduce liver-related events in patients with chronic hepatitis B. This study aimed to determine whether alanine aminotransferase normalization using potent antiviral agents was related to hepatocellular carcinoma development. From 2007 to 2017, we included 610 patients with chronic hepatitis B who received entecavir or tenofovir disoproxil fumarate. The patients were divided into the alanine aminotransferase normalization group (Gr.1) and non-normalization group (Gr.2) within a year of potent antiviral treatment. Liver-related events included hepatic encephalopathy, variceal bleeding, and ascites. The mortality rate and hepatocellular carcinoma incidence were investigated for each group. The patients who showed ALT normalization at 1 year of treatment were 397 (65.1%) of 610. During a median follow-up period of 86 months, 65 (10.7%) patients developed hepatocellular carcinoma. The cumulative incidence of hepatocellular carcinoma was significantly lower in Gr.1 than in Gr.2 (<i>p</i> < 0.001). Risk factors for alanine aminotransferase non-normalization were body mass index, cholesterol, and liver cirrhosis at baseline. Male sex, age, platelet level, alcohol use, presence of cirrhosis at baseline, and non-normalization after 1 year of treatment were independent risk factors for hepatocellular carcinoma. Alanine aminotransferase normalization within 1 year of initiating antiviral agents reduces the risk of hepatocellular carcinoma development.https://www.mdpi.com/2077-0383/10/9/1840alt normalizationhccentecavirtenofovir
collection DOAJ
language English
format Article
sources DOAJ
author Sehwa Kim
Yoonseok Lee
Soo Min Bang
Haein Bak
Sun Young Yim
Young Sun Lee
Yang Jae Yoo
Young Kul Jung
Ji Hoon Kim
Yeon Seok Seo
Hyung Joon Yim
Soon Ho Um
Kwan Soo Byun
Jong Eun Yeon
spellingShingle Sehwa Kim
Yoonseok Lee
Soo Min Bang
Haein Bak
Sun Young Yim
Young Sun Lee
Yang Jae Yoo
Young Kul Jung
Ji Hoon Kim
Yeon Seok Seo
Hyung Joon Yim
Soon Ho Um
Kwan Soo Byun
Jong Eun Yeon
Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
Journal of Clinical Medicine
alt normalization
hcc
entecavir
tenofovir
author_facet Sehwa Kim
Yoonseok Lee
Soo Min Bang
Haein Bak
Sun Young Yim
Young Sun Lee
Yang Jae Yoo
Young Kul Jung
Ji Hoon Kim
Yeon Seok Seo
Hyung Joon Yim
Soon Ho Um
Kwan Soo Byun
Jong Eun Yeon
author_sort Sehwa Kim
title Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
title_short Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
title_full Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
title_fullStr Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
title_full_unstemmed Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
title_sort early normalization of alanine aminotransferase during antiviral therapy reduces risk of hepatocellular carcinoma in hbv patients
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2021-04-01
description Potent antiviral agents effectively reduce liver-related events in patients with chronic hepatitis B. This study aimed to determine whether alanine aminotransferase normalization using potent antiviral agents was related to hepatocellular carcinoma development. From 2007 to 2017, we included 610 patients with chronic hepatitis B who received entecavir or tenofovir disoproxil fumarate. The patients were divided into the alanine aminotransferase normalization group (Gr.1) and non-normalization group (Gr.2) within a year of potent antiviral treatment. Liver-related events included hepatic encephalopathy, variceal bleeding, and ascites. The mortality rate and hepatocellular carcinoma incidence were investigated for each group. The patients who showed ALT normalization at 1 year of treatment were 397 (65.1%) of 610. During a median follow-up period of 86 months, 65 (10.7%) patients developed hepatocellular carcinoma. The cumulative incidence of hepatocellular carcinoma was significantly lower in Gr.1 than in Gr.2 (<i>p</i> < 0.001). Risk factors for alanine aminotransferase non-normalization were body mass index, cholesterol, and liver cirrhosis at baseline. Male sex, age, platelet level, alcohol use, presence of cirrhosis at baseline, and non-normalization after 1 year of treatment were independent risk factors for hepatocellular carcinoma. Alanine aminotransferase normalization within 1 year of initiating antiviral agents reduces the risk of hepatocellular carcinoma development.
topic alt normalization
hcc
entecavir
tenofovir
url https://www.mdpi.com/2077-0383/10/9/1840
work_keys_str_mv AT sehwakim earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT yoonseoklee earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT soominbang earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT haeinbak earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT sunyoungyim earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT youngsunlee earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT yangjaeyoo earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT youngkuljung earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT jihoonkim earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT yeonseokseo earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT hyungjoonyim earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT soonhoum earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT kwansoobyun earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
AT jongeunyeon earlynormalizationofalanineaminotransferaseduringantiviraltherapyreducesriskofhepatocellularcarcinomainhbvpatients
_version_ 1721512016493936640

Similar Items